Table 6. Synergistic effect of miR-125b and classical risk factors in CHD patients and controls.
| Classical risk | miR-125b | CHD | Controls | OR (95% CI) | Pvalue |
|---|---|---|---|---|---|
| Age | |||||
| 0 | 0 | 13 | 18 | 1 | 0.002 |
| 0 | 1 | 8 | 17 | 0.652(0.216 ~ 1.962) | 0.446 |
| 1 | 0 | 12 | 13 | 1.278(0.443 ~ 3.691) | 0.650 |
| 1 | 1 | 33 | 10 | 4.569(1.673 ~ 12.479) | 0.003 |
| Sex | |||||
| 0 | 0 | 6 | 14 | 1 | 0.085 |
| 0 | 1 | 6 | 7 | 2.00(0.469 ~ 8.530) | 0.349 |
| 1 | 0 | 19 | 17 | 2.608(0.819 ~ 8.309) | 0.105 |
| 1 | 1 | 35 | 20 | 4.083(1.355 ~ 12.303) | 0.012 |
| CR | |||||
| 0 | 0 | 12 | 22 | 1 | 0.016 |
| 0 | 1 | 14 | 16 | 1.604(0.587 ~ 4.381) | 0.357 |
| 1 | 0 | 13 | 8 | 2.979(0.965 ~ 9.196) | 0.058 |
| 1 | 1 | 26 | 10 | 4.767(1.731 ~ 13.130) | 0.003 |
| FBG | |||||
| 0 | 0 | 13 | 24 | 1 | 0.017 |
| 0 | 1 | 21 | 20 | 1.938(0.779 ~ 4.822) | 0.155 |
| 1 | 0 | 12 | 6 | 3.692(1.123 ~ 12.136) | 0.031 |
| 1 | 1 | 18 | 6 | 5.538(1.764 ~ 17.391) | 0.003 |
| HDL-C | |||||
| 0 | 0 | 10 | 21 | 1 | 0.009 |
| 0 | 1 | 16 | 18 | 1.867(0.680 ~ 5.126) | 0.226 |
| 1 | 0 | 15 | 9 | 3.500(1.144 ~ 10.706) | 0.028 |
| 1 | 1 | 23 | 8 | 6.037(2.006 ~ 18.173) | 0.001 |
CR, creatinine; FBG, fasting blood glucose; HDL-C, fasting high-density lipoprotein cholesterol.
The value of each miRNA-125b means the relative mount calculated by 2−Δct method.